KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for Arbutus Biopharma (ABUS) over the last 6 years, with Sep 2025 value amounting to $541,000.

  • Arbutus Biopharma's Amortizatization of Intangibles fell 44.96% to $541,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 0.67%. This contributed to the annual value of $3.1 million for FY2024, which is 42.76% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Amortizatization of Intangibles of $541,000 as of Q3 2025, which was down 19.01% from $668,000 recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Amortizatization of Intangibles high stood at $983,000 for Q3 2024, and its period low was -$300,000 during Q3 2021.
  • Over the past 3 years, Arbutus Biopharma's median Amortizatization of Intangibles value was $658,000 (recorded in 2023), while the average stood at $659,818.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first crashed by 8,050.00% in 2021, then surged by 743.37% in 2023.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Amortizatization of Intangibles stood at -$246,000 in 2021, then skyrocketed by 191.06% to $224,000 in 2022, then spiked by 176.34% to $619,000 in 2023, then surged by 49.11% to $923,000 in 2024, then plummeted by 44.96% to $541,000 in 2025.
  • Its Amortizatization of Intangibles stands at $541,000 for Q3 2025, versus $668,000 for Q2 2025 and $718,000 for Q1 2025.